{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:21:45Z","timestamp":1791235305961,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","amjmed.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.amjmed.2024.09.019","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:56:54Z","timestamp":1727827014000},"page":"269-276.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes"],"prefix":"10.1016","volume":"138","author":[{"given":"Keren","family":"Meir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Niznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Avnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Zoref-Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1472","authenticated-orcid":false,"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2024.09.019_bib0001","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.amjmed.2024.09.019_bib0002","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0003","series-title":"Handbook of Systemic Autoimmune Diseases, Vol 12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/B978-0-444-63655-3.00015-6","article-title":"Primary prophylaxis in patients with positive antiphospholipid antibodies","author":"Cuadrado","year":"2017"},{"issue":"2","key":"10.1016\/j.amjmed.2024.09.019_bib0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2018-213846","article-title":"Management of antiphospholipid syndrome","volume":"78","author":"Uthman","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.amjmed.2024.09.019_bib0005","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.amjmed.2024.09.019_bib0006","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.amjmed.2024.09.019_bib0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.amjmed.2024.09.019_bib0008","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.amjmed.2024.09.019_bib0009","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.amjmed.2024.09.019_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.09.019_bib0011","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.amjmed.2024.09.019_bib0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ebiom.2016.04.013","article-title":"Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF trials","volume":"8","author":"Proietti","year":"2016","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.amjmed.2024.09.019_bib0014","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.amjmed.2024.09.019_bib0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.amjmed.2024.09.019_bib0016","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjmed.2024.09.019_bib0017","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2024.09.019_bib0018","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2015.10.105","article-title":"Antiphospholipid syndrome and anticoagulation quality: a clinical challenge","volume":"244","author":"Pastori","year":"2016","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.amjmed.2024.09.019_bib0020","first-page":"137","article-title":"Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic","volume":"96","author":"Wittkowsky","year":"2006","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.amjmed.2024.09.019_bib0021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/ljms.ljms_45_22","article-title":"Evaluating quality of anticoagulation management among antiphospholipid syndrome patients: an observational cohort study","volume":"6","author":"Alhmoud","year":"2022","journal-title":"Libyan J Med Sci"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0022","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost."},{"issue":"9","key":"10.1016\/j.amjmed.2024.09.019_bib0023","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"STH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-12-14","article-title":"Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression","volume":"12","author":"Mearns","year":"2014","journal-title":"Thromb J"},{"issue":"2","key":"10.1016\/j.amjmed.2024.09.019_bib0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2015.06.007","article-title":"Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink","volume":"136","author":"Macedo","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.amjmed.2024.09.019_bib0026","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.55563\/clinexprheumatol\/cc5taf","article-title":"Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience","volume":"39","author":"Agmon-Levin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.09.019_bib0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2024.09.019_bib0028","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2023.08.001","article-title":"A new strategy for anticoagulation: the factor XI inhibitors","volume":"116","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"22","key":"10.1016\/j.amjmed.2024.09.019_bib0029","doi-asserted-by":"crossref","first-page":"16270","DOI":"10.3390\/ijms242216270","article-title":"Factor XI in carriers of antiphospholipid antibodies: elevated levels associated with symptomatic thrombotic cases, while low levels linked to asymptomatic cases","volume":"24","author":"Pag\u00e1n-Escribano","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:26:53Z","timestamp":1739183213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324006235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0002934324006235"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.09.019","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}